A Phase 2 interventional study of Valbenazine in Tourette Syndrome, sponsored by Neurocrine Biosciences. Completed at 13 sites in United States. Open to participants aged 6 Years to 64 Years. Per ClinicalTrials.gov, last updated 2021-04-29.
Sponsored by Neurocrine Biosciences · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 139 studies in Tourette Syndrome with a site in United States — 20 open to participants now, 24 under way, 1 of them phase 3. Tourette Syndrome · United States.
Among the 139 studies in Tourette Syndrome with a site in United States, this one is the 12th largest by enrollment of the 105 interventional ones that give a count, is one of 5 that started in 2016, is one of 26 in phase 2, and was the 76th registered.
240 studies on the registry are indexed under Tourette Syndrome; 40 are open to participants now.
Browse Tourette Syndrome studies →20 of the 139 studies in Tourette Syndrome with a site in United States are open now. Recruiting first, the newest first:
University of Minnesota · Sites in United States
Ages 12–17
University of Minnesota · Sites in United States
Ages 12–21
University of Utah · Sites in United States
Ages 8–17
Vanderbilt University Medical Center · Sites in United States
Ages 11–17 · Healthy volunteers
Boston Children's Hospital · Sites in United States
Ages 0–18
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 33 Tourette Syndrome studies recruiting now, 9 (27%) set no upper age limit and 22 (67%) stop at 75 or younger; 20 take children under 18; 9 take healthy volunteers.
This study: 6 Years to 64 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
139 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 30 · Phase 3 12 · Phase 4 8
First in 1988; this study’s year is marked. 5 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 155 is above the median of 36 across 183 interventional studies indexed under Tourette Syndrome.
Median enrollment 33 across the 105 interventional studies, 90 across the 33 observational. Of the 106 that completed or were terminated, 45 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
34 of 139 have an industry lead sponsor. The 10 most frequent:
Neurocrine Biosciences is the lead sponsor of 87 studies on the registry; 17 are open to participants now.
Of its 35 completed or terminated interventional studies of FDA-regulated products, 23 (66%) have results posted.
Neurocrine Biosciences has 8 studies filed under Tourette Syndrome — fewer than ten, so there is no comparison to draw.
6 of the studies in Tourette Syndrome with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05558566Yale UniversityNeurofeedback From the Supplementary Motor Area for Tourette Syndrome | 2026-12-20 |
| NCT01075672Massachusetts General HospitalOutcomes of Cognitive Behavioral Therapy (CBT) Interventions Provided by Unlicensed Professionals | 2027-01 |
| NCT03914664Vanderbilt University Medical CenterNeural Correlates of Sensory Phenomena in Tourette Syndrome | 2027-02-28 |
| NCT04851678Vanderbilt University Medical CenterLongitudinal Impact of Stressors in Adults With Tourette Syndrome | 2027-03-01 |
| NCT05126888Neurothera Labs Inc.SCI-110 in the Treatment of Tourette Syndrome | 2027-10 |
Add all 6 to your calendar (.ics) → With an account.
Among the 139 studies in Tourette Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Phase 2, open-label, fixed-dose titration study to evaluate the safety and tolerability of NBI-98854 administered once daily for a total of 24 weeks in children, adolescents, and adults with Tourette Syndrome (TS).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Children (6 to 11 years of age) received valbenazine 10 mg once daily for 4 weeks. At the end of Week 4, investigators could escalate the dose to 20 mg or continue with the participant's current dose for the remainder of the treatment period.
Drug: Valbenazine
Adolescents (12 to 17 years of age) received valbenazine 20 mg once daily for 4 weeks. At the end of Week 4, investigators could escalate the dose to 40 mg or continue with the participant's current dose for the remainder of the treatment period.
Drug: Valbenazine
Adults (18 to 64 years of age) received valbenazine 40 mg once daily for 4 weeks. At the end of Week 4, investigators could escalate the dose to 80 mg or continue with the participant's current dose for the remainder of the treatment period.
Drug: Valbenazine
Also known as: NBI-98854
Frequency of Treatment-emergent Adverse Events (TEAEs)
A TEAE is an adverse event not present prior to the initiation of study drug dosing, or is an already present event that worsens either in intensity or frequency following the initiation of study drug dosing.
Time frame: Baseline through Week 28
The study enrolled male and female children (6 to 11 years of age), adolescents (12 to 17 years of age), and adults (18 to 64 years of age) from 34 centers in the United States. Participants must have a clinical diagnosis of Tourette Syndrome (TS) and must have previously completed participation in Study NB-98854-1501 or Study NBI-98854-1505. The first and last participant were enrolled on 25 July 2016 and 14 April 2017, respectively.
| Milestone | Valbenazine (Children) | Valbenazine (Adolescents) | Valbenazine (Adults) |
|---|---|---|---|
| Started | 33 | 41 | 81 |
| Safety analysis set | 33 | 40 | 79 |
| Completed | 23 | 32 | 49 |
| Not completed | 10 | 9 | 32 |
| Withdrew: Adverse event | 1 | 2 | 14 |
| Withdrew: Protocol violation | 0 | 1 | 1 |
| Withdrew: Withdrawal by subject | 8 | 6 | 9 |
| Withdrew: Lost to follow-up | 1 | 0 | 4 |
| Withdrew: Physician decision | 0 | 0 | 4 |
A TEAE is an adverse event not present prior to the initiation of study drug dosing, or is an already present event that worsens either in intensity or frequency following the initiation of study drug dosing.
| Participants | Valbenazine (Children) | Valbenazine (Adolescents) | Valbenazine (Adults) |
|---|---|---|---|
| Frequency of Treatment-emergent Adverse Events (TEAEs) | 20 | 29 | 68 |
Collected over Up to 28 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Valbenazine (Children) | 0/33 (0%) | 0/33 (0%) | 19/33 (57.6%) |
| Valbenazine (Adolescents) | 0/40 (0%) | 0/40 (0%) | 22/40 (55%) |
| Valbenazine (Adults) | 0/79 (0%) | 2/79 (2.5%) | 57/79 (72.2%) |
| Event | Valbenazine (Children) | Valbenazine (Adolescents) | Valbenazine (Adults) |
|---|---|---|---|
| Extrapyramidal disorderNervous system disorders | 0/33 | 0/40 | 1/79 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 0/33 | 0/40 | 1/79 |
| Event | Valbenazine (Children) | Valbenazine (Adolescents) | Valbenazine (Adults) |
|---|---|---|---|
| SomnolenceNervous system disorders | 3/33 | 8/40 | 16/79 |
| SedationNervous system disorders | 3/33 | 8/40 | 12/79 |
| FatigueGeneral disorders | 5/33 | 4/40 | 13/79 |
| HeadacheNervous system disorders | 5/33 | 5/40 | 5/79 |
| Upper respiratory tract infectionInfections and infestations | 2/33 | 2/40 | 11/79 |
| InsomniaPsychiatric disorders | 2/33 | 5/40 | 3/79 |
| IrritabilityGeneral disorders | 4/33 | 0/40 | 2/79 |
| VomitingGastrointestinal disorders | 3/33 | 2/40 | 1/79 |
| DepressionPsychiatric disorders | 1/33 | 0/40 | 7/79 |
| Weight increasedInvestigations | 2/33 | 3/40 | 3/79 |
Safety analysis set, which includes all participants who received at least one dose of study drug and have any postbaseline data.
| Age, Continuous(Years) | Valbenazine (Children) | Valbenazine (Adolescents) | Valbenazine (Adults) | Total |
|---|---|---|---|---|
| Mean | 9.5 ± 1.5 | 13.7 ± 1.4 | 34.6 ± 12.9 | 23.6 ± 14.8 |
| Sex: Female, Male(Participants) | Valbenazine (Children) | Valbenazine (Adolescents) | Valbenazine (Adults) | Total |
|---|---|---|---|---|
| Female | 7 | 8 | 25 | 40 |
| Male | 26 | 32 | 54 | 112 |
| Ethnicity (NIH/OMB)(Participants) | Valbenazine (Children) | Valbenazine (Adolescents) | Valbenazine (Adults) | Total |
|---|---|---|---|---|
| Hispanic or Latino | 3 | 6 | 4 | 13 |
| Not Hispanic or Latino | 30 | 34 | 75 | 139 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Valbenazine (Children) | Valbenazine (Adolescents) | Valbenazine (Adults) | Total |
|---|---|---|---|---|
| Race — American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Race — Asian | 0 | 0 | 1 | 1 |
| Race — Black or African American | 3 | 2 | 1 | 6 |
| Race — White | 30 | 35 | 76 | 141 |
| Race — Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Race — Other | 0 | 1 | 0 | 1 |
| Race — Multiple | 0 | 2 | 1 | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jul 2016 to primary completion in Nov 2017, 15 months.
Results were first posted in Apr 2021, 3 years 5 months after primary completion. A results delay was requested in Mar 2019.
Of 19 phase 2 interventional studies under Tourette Syndrome, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 42. This study's 15 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Valbenazine